Comparative proteomic analysis of antimony-resistant and-susceptible Leishmania braziliensis and Leishmania infantum chagasi lines

Molecular and Biochemical Parasitology

Volumn 190, Issue 2, 2013, Pages 63-75

  Matrangolo, Fabiana S V ^a,b   Liarte, Daniel B ^a,c   Andrade, Laila C ^a   De Melo, Melina F ^a   Andrade, Juvana M ^a   Ferreira, Rafael F ^a   Santiago, André S ^d   Pirovani, Carlos P ^d   Silva Pereira, Rosiane A ^a   Murta, Silvane M F ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^c FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^d DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

Author keywords

2 DE; Antimony resistance; Cyclophilin A; Leishmania braziliensis; Leishmania infantum chagasi; Proteome; Pteridine reductase; Tryparedoxin peroxidase

Indexed keywords

ALPHA TUBULIN; AMIDASE; AMINOACYLASE; ANTIMONY; ANTIOXIDANT; CHAPERONIN 60; CYCLOPHILIN A; CYTOSKELETON PROTEIN; GLUCOSE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 83; NITRILASE; PEROXIDASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PTERIDINE; PTERIDINE REDUCTASE; TRYPAREDOXIN; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOSKELETON; LEISHMANIA BRAZILIENSIS; LEISHMANIA CHAGASI; LEISHMANIA INFANTUM; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; STRESS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM;

2-DE; ANTIMONY RESISTANCE; CYCLOPHILIN-A; L. (L.) INFANTUM CHAGASI SBIII-RESISTANT; L. (L.) INFANTUM CHAGASI WILD-TYPE; L. (V.) BRAZILIENSIS SBIII-RESISTANT; L. (V.) BRAZILIENSIS WILD-TYPE; LBSBR; LBWTS; LCSBR; LCWTS; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM CHAGASI; MASS SPECTROMETRY; MS; POTASSIUM ANTIMONYL TARTRATE; PROTEOME; PTERIDINE REDUCTASE; SBIII; TRYPAREDOXIN PEROXIDASE; TWO-DIMENSIONAL GEL ELECTROPHORESIS;

ANTIMONY; DRUG RESISTANCE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; PROTOZOAN PROTEINS;

EID: 84886907764     PISSN: 01666851     EISSN: 18729428     Source Type: Journal    
DOI: 10.1016/j.molbiopara.2013.06.006     Document Type: Article

References (54)

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012;7: e35671.
2. Marsden PD. Mucosal leishmaniasis (espundia Escomel, 1911). Transactions of the Royal Society of Tropical Medicine and Hygiene 1986;80: 859-76.
3. Gontijo CMF, Melo MN. Leishmaniose Visceral no Brasil: quadro atual, desafios e perspectivas Visceral Leishmaniasis in Brazil. Revista Brasileira de Epidemiologia 2004;7:338-49.
4. Berman JD, Waddell D, Hanson BD. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrobial Agents and Chemotherapy 1985;27:916-20. (Pubitemid 15062736)
5. Berman JD, Hanson WL, Lovelace JK, Waits VB, Jackson JE, Chapman WL, et al. Activity of purine analogs against Leishmania donovani in vivo. Antimicrobial Agents and Chemotherapy 1987;31:111-3. (Pubitemid 17212670)
6. Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. Journal of Biological Chemistry 2004;279:39925-32. (Pubitemid 39258265)
7. Sundar S. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine and International Health 2001;6:849-54. (Pubitemid 33010870)
8. Guerin PJ, Olliaro P, Nosten F, Druilhe P, Laxminarayan R, Binka F, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infectious Diseases 2002;2:564-73. (Pubitemid 34966359)
9. Croft S, Sundar S, Fairlamb A. Drug resistance in leishmaniasis. Clinical Microbiology Reviews 2006;19:111-26. (Pubitemid 43157649)
10. Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. Journal of Biological Chemistry 2001;276:3971-6.
11. Mukhopadhyay R, Dey S, Xu N, Gage D, Lightbody J, Ouellette M, et al. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proceedings of the National Academy of Sciences of the United States of America 1996;93:10383-7. (Pubitemid 26314631)
12. McNicoll F, Drummelsmith J, Müller M, Madore E, Boilard N, Ouellette M, et al. A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics 2006;6:3567-81. (Pubitemid 44000186)
13. Cuervo P, Domont GB, De Jesus JB. Proteomics of trypanosomatids of human medical importance. Journal of Proteomics 2010;73:845-67.
14. Peacock C, Seeger K, Harris D, Murphy L. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nature Genetics 2007;39:839-47. (Pubitemid 47014491)
15. Thiel M, Bruchhaus I. Comparative proteome analysis of Leishmania donovani at different stages of transformation from promastigotes to amastigotes. Medical Microbiology and Immunology 2001;190:33-6. (Pubitemid 33079354)
16. El Fakhry Y, Ouellette M, Papadopoulou B. A proteomic approach to identify developmentally regulated proteins in Leishmania infantum. Proteomics 2002;2:1007-17.
17. Nugent PG, Karsani Sa, Wait R, Tempero J, Smith DF. Proteomic analysis of Leishmania mexicana differentiation. Molecular and Biochemical Parasitology 2004;136:51-62. (Pubitemid 38597120)
18. Walker J, Acestor N, Gongora R, Quadroni M, Segura I, Fasel N, et al. Comparative protein profiling identifies elongation factor-1beta and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis. Molecular and Biochemical Parasitology 2006;145:254-64. (Pubitemid 43083367)
19. Forgber M, Basu R, Roychoudhury K, Theinert S, Roy S, Sundar S, et al. Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS ONE 2006;1:e40.
20. Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, Shasany AK, et al. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 2007;7:816-23. (Pubitemid 46450658)
21. Drummelsmith J, Brochu V, Girard I, Messier N, Ouellette M. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Molecular and Cellular Proteomics 2003;2:146-55.
22. Sharma S, Singh G, Chavan HD, Dey CS. Proteomic analysis of wild type and arsenite-resistant Leishmania donovani. Experimental Parasitology 2009;123:369-76.
23. Daneshvar H, Wyllie S, Phillips S, Hagan P, Burchmore R. Comparative proteomics profiling of a gentamicin-attenuated Leishmania infantum cell line identifies key changes in parasite thiol-redox metabolism. Journal of Proteomics 2012;75:1463-71.
24. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M. A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Molecular and Cellular Proteomics 2007;6:88-101. (Pubitemid 46152694)
25. Kumar A, Sisodia B, Misra P. Proteome mapping of overexpressed membraneenriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania. British Journal of Clinical Pharmacology 2010;70:609-17.
26. Biyani N, Singh AK, Mandal S, Chawla B, Madhubala R. Differential expression of proteins in antimony-susceptible and -resistant isolates of Leishmania donovani. Molecular and Biochemical Parasitology 2011;179:91-9.
27. El Fadili K, Drummelsmith J, Roy G, Jardim A, Ouellette M. Down regulation of KMP-11 in Leishmania infantum axenic antimony resistant amastigotes as revealed by a proteomic screen. Experimental Parasitology 2009;123:51-7.
28. Walker J, Gongora R, Vasquez J-J, Drummelsmith J, Burchmore R, Roy G, et al. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Molecular and Biochemical Parasitology 2012;183:166-76.
29. Liarte DB, Murta SMF. Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species. Parasitology Research 2010;107:205-12.
30. Marzochi MCde A, Marzochi KBF. Tegumentary and visceral Leishmaniases in Brazil - emerging anthropozoonosis and possibilities for their control. Cadernos de Saúde Pública 1994;10:359-75.
31. Shaw JJ. Further thoughts on the use of the name Leishmania for the aetiological agent of American visceral leishmaniasis. Memorias do Instituto Oswaldo Cruz 2006;101:577-9. (Pubitemid 44285804)
32. Neuhoff V, Arold N, Taube D, Ehrhardt W. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988;9:255-62.
33. Pajuaba AC, Silva DA, Almeida KC, Cunha-Junior JP, Pirovani CP, Camillo LR, et al. Immunoproteomics of Brucella abortus reveals differential antibody profiles between S19-vaccinated and naturally infected cattle. Proteomics 2012;12:820-31.
34. Nogueira FB, Ruiz JC, Robello C, Romanha AJ, Murta SMF. Molecular characterization of cytosolic and mitochondrial tryparedoxin peroxidase in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Parasitology Research 2009;104:835-44.
35. Larreta R, Soto M, Quijada L, Folgueira C, Abanades DR, Alonso C, et al. The expression of HSP83 genes in Leishmania infantum is affected by temperature and by stage-differentiation and is regulated at the levels of mRNA stability and translation. BMC Molecular Biology 2004;5:3.
36. Folgueira C, Requena JM. A postgenomic view of the heat shock proteins in kinetoplastids. FEMS Microbiology Review 2007;31:359-77. (Pubitemid 46920247)
37. Lawrence F, Robert-Gero M. Induction of heat shock and stress proteins promastigotes of three Leishmania species. Proceedings of the National Academy of Sciences of the United States of America 1985;82:4414-7. (Pubitemid 15234244)
38. Do Monte-Neto RL, Coelho AC, Raymond F, Légaré D, Corbeil J, Melo MN, et al. Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLOS Neglected Tropical Diseases 2011;5:e1167.
39. Brochu C, Haimeur A, Ouellette M. The heat shock protein HSP70 and heat shock cognate protein HSC70 contribute to antimony tolerance in the protozoan parasite leishmania. Cell Stress and Chaperones 2004;9:294-303. (Pubitemid 39457433)
40. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resistance Updates 2004;7:257-66. (Pubitemid 39469098)
41. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 1998;92:351-66. (Pubitemid 28093013)
42. Obchoei S, Wongkhan S, Wongkham C. Cyclophilin A: potential functions and therapeutic target for human cancer. Medical Science Monitor 2009;15:221-32.
43. Jayanarayan KG, Dey CS. Resistance to arsenite modulates expression of betaand gamma-tubulin and sensitivity to paclitaxel during differentiation of Leishmania donovani. Parasitology Research 2002;88:754-9.
44. Jayanarayan KG, Dey CS. Altered expression, polymerisation and cellular distribution of alpha-/beta-tubulins and apoptosis-like cell death in arsenite resistant Leishmania donovani promastigotes. International Journal for Parasitology 2004;34:915-25. (Pubitemid 38813253)
45. Nare B, Hardy LW, Beverley SM. The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major. Journal of Biological Chemistry 1997;272:13883-91. (Pubitemid 27224830)
46. Nare B, Garraway LA, Vickers TJ, Beverley SM. PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major. Current Genetics 2009;55:287-99.
47. Turrens JF. Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. Molecular Aspects of Medicine 2004;25:211-20. (Pubitemid 38401943)
48. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Molecular and Biochemical Parasitology 2010;173:162-4.
49. Lamberti, M. Caraglia A, Longo O, Marra M, Abbruzzese A, Arcari P. The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids 2004;26:443-8. (Pubitemid 39093149)
50. Ponder EL, Bogyo M. Ubiquitin-like modifiers and their deconjugating enzymes in medically important parasitic protozoa. Eukaryotic Cell 2007;6: 1943-52. (Pubitemid 350221263)
51. Cuervo P, De Jesus JB, Saboia-Vahia L, Mendonça-Lima L, Domont GB, Cupolillo E. Proteomic characterization of the released/secreted proteins of Leishmania (Viannia) braziliensis promastigotes. Journal of Proteomics 2009;73: 79-92.
52. Mani J, Güttinger A, Schimanski B, Heller M, Acosta-Serrano A, Pescher P, et al. Alba-domain proteins of Trypanosoma brucei are cytoplasmic RNAbinding proteins that interact with the translation machinery. PLoS ONE 2011;6:e22463.
53. Rosenzweig D, Smith D, Myler PJ, Olafson RW, Zilberstein D. Post-translational modification of cellular proteins during Leishmania donovani differentiation. Proteomics 2008;8:1843-50. (Pubitemid 351678285)
54. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biology and Disease 2003;2:14.